Immunomodulatory Effects of Maraviroc Intensification in HIV-infected Individuals with Incomplete CD4+ T Cell Recovery during Suppressive Antiretroviral Therapy

Trial Profile

Immunomodulatory Effects of Maraviroc Intensification in HIV-infected Individuals with Incomplete CD4+ T Cell Recovery during Suppressive Antiretroviral Therapy

Completed
Phase of Trial: Phase II

Latest Information Update: 21 Mar 2011

At a glance

  • Drugs Maraviroc (Primary) ; Antiretrovirals
  • Indications HIV infections
  • Focus Therapeutic Use
  • Most Recent Events

    • 21 Mar 2011 New trial record
    • 02 Mar 2011 Results presented at the 18th Conference on Retroviruses and Opportunistic Infections.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top